UniProtKB/SwissProt variant VAR

Variant information

Variant position:

101

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

US

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Cysteine (C) to Phenylalanine (F) at position 101 (C101F, p.Cys101Phe).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from medium size and polar (C) to large size and aromatic (F)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In RBMX1A; unknown pathological significance.

Any additional useful information about the variant.

Sequence information

Variant position:

101

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

323

The length of the canonical sequence.

Location on the sequence:

VAKDNKILCNKCTTREDSPK C KGCFKAIVAGDQNVEYKGTV

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VAKDNK-----------------------------------------------------------------------------------------------ILCNKCTTREDSPKCK-------------------------------------------------------------------GCFKA-----------IVAGDQNV----EYKGTV

Mouse                         VSKDGK-----------------------------------

Rat                           VSKDGK-----------------------------------

Baker's yeast                 ILPEQERNDD-------------------------------

Fission yeast                 LLPEGSEEDGHLKETGITPLSLQQGKIAYSDEFGGKPTGSF

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 323	Four and a half LIM domains protein 1
Domain	101 – 153	LIM zinc-binding 2
Cross	86 – 86	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)

Literature citations

Novel FHL1 mutations in fatal and benign reducing body myopathy.
Shalaby S.; Hayashi Y.K.; Nonaka I.; Noguchi S.; Nishino I.;
Neurology 72:375-376(2009)
Cited for: VARIANTS RBMX1A PHE-101 AND TYR-150; VARIANTS RBMX1B 102-LYS--CYS-104 DEL AND ARG-104;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13642: Variant p.Cys101Phe